Shares soar after $900m Novartis and Glaxo deal
GlaxoSmithKline and Swiss pharmaceuticals rival Novartis have agreed to pay the other $900m (£535m) if one of them pulls out of the major medicines swap deal that will see the British giant quit trying to make blockbuster cancer treatments.
The punitive termination fees were seen as a key indicator of the pair's confidence in pulling off what is the biggest shake-up for the company since the merger of Glaxo and SmithKline Beecham. Glaxo will sell its cancer drugs to Novartis for $16bn, buying the Swiss giant's vaccines operation for $5.25bn. The pair will merge consumer health divisions to create a £6.5bn business spanning Aquafresh toothpaste, Tixylix cough mixture and Savlon. Glaxo will have a 63.5 per cent stake, and its consumer boss Emma Walmsley will run it.
Glaxo is dangling £4bn in cash proceeds from the deal to tempt investors to approve the deal at an extraordinary general meeting. Shares in the drugmaker rose 81p to 1640p.
The transaction marks a clear admission by Glaxo chief executive Sir Andrew Witty, eight years into his reign, that the company cannot compete in the cancer research field, where its treatments have suffered setbacks and only occupy 14th in the global league tables compared with Novartis's number two spot.
But it also reinforces his belief that the days of mega-mergers and acquisitions (M&A) to create behemoths covering every division of healthcare are over – in stark contrast to rival Pfizer's strategy, with the emergence of its £76bn approach for AstraZeneca. Mr Witty said: "M&A is a strategy to be used sparingly."
Glaxo's purchase of Novartis's vaccines division gives it more muscle in a fast-growing sector. Novartis's portfolio includes inoculations against meningitis, polio, rabies and tetanus as well as flu, although Glaxo will inherit Novartis's battle with the British Government over the price it charges the NHS for its meningitis B vaccine. Such pricing pressures from buyers around the world, and the impact of cheaper generic copies of medicines as they come off patent, will continue to drive major shake-ups by the drug giants, Mr Witty said.
After the deal, 70 per cent of Glaxo's revenues will come from the areas of respiratory, HIV, vaccines and the consumer joint venture.
Rainmaker brothers: Fourth massive deal
The deal is another triumph for veteran Moroccan takeover "rainmakers" Yoel and Michael Zaoui, who advised GlaxoSmithKline on what is the fourth massive deal since the brothers set up in business together just six months ago.
For two decades, they conducted some of the biggest takeovers in the world, with Yoel running Goldman Sachs's deal team and Michael Morgan Stanley's.
Since founding Zaoui & Co they have advised L'Oreal, Peugeot and Lafarge on multi-billion dollar deals.
- 1 PlayStation and Xbox hacked by Lizard Squad
- 2 Katie Hopkins speaks out on childhood obesity: 'Parents of fat children should be prosecuted for child cruelty'
- 3 The Grace Dent Christmas Questionnaire
- 4 The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
- 5 Vagina canoe artist defends herself over ‘obscenity’ charges
PlayStation and Xbox hacked by Lizard Squad
Boxing Day snowfall set to push even more bargain-hunters online for sales
Katie Hopkins speaks out on childhood obesity: 'Parents of fat children should be prosecuted for child cruelty'
The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
Postcard from... The Vatican
British actor Idris Elba cannot star as James Bond because he is black, says shock jock Rush Limbaugh
Rozanne Duncan: Ukip expels councillor for 'jaw-dropping' comments made in BBC TV interview
Germany anti-Islam protests: 17,000 march on Dresden against 'Islamification of the West'
Ukip member gets into Christmas spirit with Union Flag plea to Santa 'for our country back'
BBC director Danny Cohen: Rising UK antisemitism makes me feel more uncomfortable than ever
Alex Salmond has 'broken his word to the Scottish people' says Scottish Lib Dem leader
iJobs Money & Business
Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...
Not specified: Selby Jennings: SVP Model Validation This top tiered investment...
Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...
£43500 per annum + pension + holidays: The Jenrick Group: Night Shift Operatio...